SCHEDULE: Loewenbaum Group Discloses 13.4% Stake in CollPlant

The Loewenbaum family and associated entities have disclosed a collective beneficial ownership of 13.4% in CollPlant Biotechnologies Ltd for investment purposes.

Summary

• The Loewenbaum family and related trusts/partnerships (Reporting Persons) collectively beneficially own 1,698,533 Ordinary Shares of CollPlant Biotechnologies Ltd.
• This aggregate ownership represents 13.4% of CollPlant's total outstanding Ordinary Shares, based on 12,716,014 shares outstanding as of June 30, 2025.
• The acquisitions were made for investment purposes, and the Reporting Persons currently have no present plans or proposals that would result in actions such as mergers, asset sales, or changes in management.
• They intend to continuously review their investment and may form plans or proposals for such actions in the future, which would necessitate an amendment to this filing.
• Recent open market purchases by various Reporting Persons occurred between July 25, 2025, and July 31, 2025, at prices ranging from $2.25 to $2.41 per share.

Sentiment

Score: 7

Explanation: The filing indicates a significant and recently increased stake by a group of affiliated investors, suggesting confidence in the company's value. While it's a disclosure of ownership rather than operational news, the accumulation of shares by a substantial investor group is generally a positive signal. The explicit mention of potential future actions, though currently absent, adds a layer of potential future engagement.

Positives

• Significant investor confidence demonstrated by a collective 13.4% stake held by an affiliated group.
• Recent open market purchases by George Walter Loewenbaum and associated trusts indicate continued belief in the company's value at current price levels.

Risks

• The Reporting Persons may, in the future, form plans or proposals related to the Issuer's corporate structure, management, or business, which could introduce uncertainty or strategic shifts.
• Investment decisions are subject to market conditions, the Issuer's business prospects, and general economic conditions, which could impact the value of the stake.

Future Outlook

The Reporting Persons intend to continuously review their investment in CollPlant Biotechnologies Ltd. Depending on market conditions, the Issuer's business, and other factors, they may form plans or proposals related to the company's structure, management, or business, which would be disclosed in an amended filing.

Industry Context

This filing indicates a significant stake held by a group of affiliated investors in a biotechnology company. Such substantial ownership by a single group can signal long-term confidence in the company's prospects within the biotech sector, which is often characterized by high R&D costs and potential for significant returns from successful product development.

Comparison to Industry Standards

• A 13.4% beneficial ownership stake by an affiliated group is a substantial position, often indicating a significant level of conviction in the company's long-term value proposition. This level of ownership is comparable to that seen in other small-to-mid cap biotechnology companies where early investors or founding families maintain considerable influence.
• The stated purpose of 'investment purposes' without immediate plans for activism is standard for many large passive stakes, but the explicit mention of potential future actions (Item 4(a)-(j)) suggests a readiness to engage if deemed necessary, similar to how activist investors might initially position themselves.

Legal Proceedings

• None of the Reporting Persons nor any general partner or trustee of the Reporting Entities have been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) during the last five years.
• None of the Reporting Persons nor any general partner or trustee of the Reporting Entities were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws during the last five years.

Related Party Transactions

• The Reporting Persons have entered into a Joint Filing Agreement, dated January 28, 2025, to coordinate their filing of this Schedule 13D.

Stakeholder Impact

• Shareholders: The disclosure of a significant 13.4% stake by an affiliated group could be viewed positively, signaling strong investor conviction. The potential for future engagement by this group could influence strategic direction.
• Management: Management may need to consider the implications of a large, potentially active, shareholder group, especially if the Reporting Persons decide to pursue actions outlined in Item 4(a)-(j).

Next Steps

• The Reporting Persons will continue to review their investment in CollPlant Biotechnologies Ltd.
• If the Reporting Persons form any plans or proposals related to the Issuer's corporate actions (e.g., mergers, asset sales, management changes), they will file an amendment to this Schedule 13D.

Key Dates

Recommendation

This Schedule 13D filing primarily discloses a significant beneficial ownership stake by the Loewenbaum family and associated entities in CollPlant Biotechnologies Ltd. The collective 13.4% stake, coupled with recent open market purchases, indicates strong conviction from this investor group. While this is a positive signal of investor confidence, the filing itself does not provide new operational or financial performance data for CollPlant. The stated purpose is for investment, with no immediate plans for corporate actions, but the possibility of future engagement is noted. Therefore, for a seasoned investor, this filing reinforces a 'hold' position for existing shareholders, suggesting continued monitoring of the company's performance and any future actions by this significant shareholder group. For potential new investors, it highlights a notable institutional interest, but further due diligence on CollPlant's fundamentals is warranted before a 'buy' decision.

Keywords

CollPlant Biotechnologies, Schedule 13D, Beneficial Ownership, Loewenbaum, Biotechnology, Investment, Shareholder Stake, Ordinary Shares, SEC Filing